This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Baxter's (BAX) New Sharesource 2.0 to Improve PD Treatment
by Zacks Equity Research
Baxter's (BAX) Sharesource 2.0 provides a more comprehensive patient treatment summary to enable faster clinical insights.
LH vs. XRAY: Which Stock Is the Better Value Option?
by Zacks Equity Research
LH vs. XRAY: Which Stock Is the Better Value Option?
Varian Medical Buys Endocare & Alicon to Boost Cancer Care
by Zacks Equity Research
Varian Medical (VAR) expects the buyouts to prove accretive to bottom line in fiscal 2020.
What's in the Offing for HEXO Corp's (HEXO) Q3 Earnings?
by Zacks Equity Research
HEXO Corp's (HEXO) recent 1,000,000 sq. ft. greenhouse expansion is likely to reflect on quarterly results.
HealthEquity (HQY) Earnings & Revenues Top Estimates in Q1
by Zacks Equity Research
Higher revenues, solid segmental performance and expansion in margins benefit HealthEquity's (HQY) Q1 earnings.
Medical Dental Supplies Industry Outlook: Growth Scope Wide
by Sreyoshi Mukherjee
Near-term prospects look bright for the Zacks Medical Dental Supplies industry, thanks to laser dentistry and robotics.
Why Is Dentsply (XRAY) Up 3.9% Since Last Earnings Report?
by Zacks Equity Research
Dentsply (XRAY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Cooper Companies (COO) Q2 Earnings & Revenues Top Estimates
by Zacks Equity Research
Higher revenues, solid segmental performance and expansion in margins benefit Cooper Companies' (COO) Q2 earnings.
Veeva Systems (VEEV) Q1 Earnings Top Estimates, View Strong
by Zacks Equity Research
Veeva Systems (VEEV) issues strong guidance for fiscal 2020.
NextGen's (NXGN) Q4 Earnings Top Estimates, Bookings Down Y/Y
by Zacks Equity Research
NextGen (NXGN) Q4 results benefit from better performing recurring segment. However, gross margin contraction remains a woe.
Globus Medical Reveals Positive Study Results for ExcelsiusGPS
by Zacks Equity Research
Results of the study of ExcelsiusGPS reached a milestone for Globus Medical (GMED) in the field of robotics-assisted, minimally invasive pedicle screw placement procedure
Can Segmental Growth Aid Cooper Companies' (COO) Q2 Earnings?
by Zacks Equity Research
Cooper (COO) expects to gain from CVI and CSI units in the fiscal second quarter.
Veeva Systems (VEEV) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
Top-line growth and solid show by Subscription services and Professional services units are likely to aid Veeva Systems (VEEV) in Q1 earnings. However, rising expenses remains a dampener.
Medtronic (MDT) Q4 Earnings Beat, Operating Margin Rises
by Zacks Equity Research
Excluding the Diabetes group, Medtronic (MDT) displays better performances at CER on the back of growth in rest of the business segments and across all geographies.
Here's Why You Should Hold On to Integra LifeSciences Stock
by Zacks Equity Research
Investor confidence is still high on growth prospects of Integra LifeSciences (IART).
QIAGEN (QGEN) to Win U. N. Accolade for QuantiFERON-TB Access
by Zacks Equity Research
This acclaim marks a giant leap for QIAGEN (QGEN) in the field of tuberculosis diagnosis.
AngioDynamics IDE Application for NanoKnife Gets FDA Nod
by Zacks Equity Research
AngioDynamics' (ANGO) pilot study is intended to support the approval of a future PMA in the United States.
Hologic Breast Health Arm Aids Strongly, Rising Costs Ail
by Zacks Equity Research
Within Breast Health, Hologic (HOLX) unveils a string of products including 3Dimensions and 3D Performance gantries, Clarity HD, SmartCurve, Affirm prone biopsy system and Brevera biopsy system.
Will RTG Again Bolster Medtronic's (MDT) Earnings in Q4?
by Zacks Equity Research
Within Neurovascular, we hope to witness strength across Medtronic's (MDT) stroke franchise with growth in stent retrievers, flow diverters, neuro access and embolic products.
ResMed Study Shows Remote Monitoring Benefits on CPAP Use
by Zacks Equity Research
Results of this study mark a remarkable feat for ResMed's (RMD) medical innovation aimed at treating people suffering from sleep apnea.
Here's Why You Should Buy Masimo (MASI) Stock Right Now
by Zacks Equity Research
Masimo (MASI) benefits from launches like Halo ION.
Avedro (AVDR) Hits a 52-Week High on Solid Growth Prospects
by Zacks Equity Research
Avedro (AVDR) gains from promising developments in recent times.
Varian Medical's CTSI Buyout to Boost Oncology Services Unit
by Zacks Equity Research
The CTSI buyout is expected to prove accretive to Varian Medical's (VAR) adjusted earnings per share during fiscal 2021.
Why Should You Hold on to Myriad Genetics (MYGN) Stock?
by Zacks Equity Research
Investor confidence is still high on growth prospects of Myriad Genetics (MYGN).
LabCorp Grows on Strong Diagnostics Arm Amid Contract Losses
by Zacks Equity Research
LabCorp's (LH) diagnostics business grows organically despite additional price reductions.